Skip to main content
AMGN
NASDAQ Life Sciences

Amgen's IMDYLLTRA Approved in Europe for Lung Cancer, Showing 40% Mortality Reduction

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$329.135
Mkt Cap
$177.637B
52W Low
$267.83
52W High
$391.29
52W Position info
23% above low
Off High info
16% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AMGN sits 23% above its 52-week low of $267.83.

Summary

The European Commission has approved Amgen's IMDYLLTRA (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy. This follows the drug's approval in China in April. IMDYLLTRA is a first-in-class T-cell engager therapy, and its approval is based on Phase 3 data showing a 40% reduction in the risk of death and an extension of median overall survival by over five months compared to standard chemotherapy. This represents a significant new treatment option for a highly aggressive cancer with limited alternatives, expanding Amgen's market opportunity in Europe for a novel and effective therapy.

At the time of this announcement, AMGN was trading at $329.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.6B. The 52-week trading range was $267.83 to $391.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $465.00 info
Change: -$12.40 (-3%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $465.00 info
Change: +$0.080 (+0.02%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $465.00 info
Change: +$2.00 (+0.43%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $465.00 info
Change: +$4.43 (+0.96%) info
Market Cap: $251.886B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $465.00 info
Change: +$16.21 (+4%) info
Market Cap: $251.886B info